Mutations in the α4-α5 allosteric lobe of RAS do not significantly impair RAS signaling or self-association.

Area of Science:

• Oncogenic signaling pathways
• Molecular mechanisms of cancer

Background:

• Mutations in HRAS, KRAS, and NRAS genes are common in human cancers, leading to constitutive RAS activation.
• RAS activation promotes downstream signaling, including RAF activation, which is linked to effector dimerization.
• The α4-α5 region of RAS has been hypothesized as a dimerization interface crucial for RAS-mediated signaling.

Purpose of the Study:

• To investigate the role of the α4-α5 region in RAS dimerization and oncogenic signaling.
• To evaluate the impact of specific amino acid substitutions in the α4-α5 region on RAS function.

Main Methods:

• Generated and analyzed single amino acid substitutions within the proposed RAS α4-α5 dimerization interface.
• Assessed the effects of these mutations on RAS self-association, downstream signaling, and cellular transformation.
• Utilized biochemical and cellular assays to probe RAS protein interactions and activity.

Main Results:

• Mutations in the α4-α5 region did not significantly impair RAS self-association, signaling, or transformation.
• Prior findings suggesting α4-α5 mediated RAS dimerization were not consistently reproduced.
• Activated RAS proteins appear to cluster, facilitating effector dimerization rather than direct RAS-RAS dimerization.

Conclusions:

• The α4-α5 region is unlikely to be a direct RAS dimerization interface.
• RAS-mediated effector activation may occur through proximity-induced effector dimerization, not RAS dimerization.
• Therapeutic strategies targeting the α4-α5 region for cancer treatment require a nonconventional approach.